Ghent, Belgium
5 March 2026
- European regulatory approval of MagNfix™, its proprietary soybean inoculant seed coating
- First commercial launch in Poland, one of Europe’s fastest-growing soybean markets
- Five new high-performance soybean varieties registered, including first 0000 maturity group (MG) ultra-early soybean variety in France
Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI[1] (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany. With regulatory approval for its biological solution MagNfix™ and an expanding portfolio of high-performance, climate-adapted soybean varieties, Protealis is now fully geared to scale commercially with ready-to-sow soybean seeds to farmers across Europe in the years to come.
“With the European regulatory approval of MagNfix™, Protealis is entering the biologicals market alongside its core activity in soybean seed breeding and commercialization in Europe. The combination of an expanding portfolio of high-performance soybean varieties and a proprietary inoculant enables an integrated, ready-to-sow solution tailored to European growing conditions. This approach supports the economic viability of soybean cultivation in more northern regions and strengthens our position for further commercial expansion. This combination of advanced genetics with proprietary biologicals can boost Europe’s domestic plant protein production in a way that works for farmers, economically and agronomically.”, said David Buckeridge, Chairman of the Board of Directors of Protealis.
The European regulatory approval of MagNfix™, Protealis’ proprietary soybean seed inoculant, is a milestone for the company’s biologicals program. MagNfix™ incorporates a Bradyrhizobium bacteria strain selected for its adaptation to European soils and is applied through a seed coating technology. In independent multi-location registration trials, the product demonstrated yield increases of +31% on average compared to reference inoculants[2] and a +7% improvement in protein content versus peers2. The formulation offers a shelf life of up to three months and is delivered as a ready-to-sow coated seed, eliminating the need for on-farm inoculation and delivering a time-efficient, scalable solution for large-scale farming operations.
At the same time, Protealis succeeded in the registration of five new soybean varieties which expand its portfolio from 9 varieties in 2025 to 14 today, spanning the 0000, 000 and 00 maturity groups. The new soybean varieties contain non-GMO soybean genetics specifically developed to thrive across colder northern and north-central European regions, including northern France, Germany and emerging eastern markets such as Poland. The new launches include PRO Hekla (MG 0000, France), the company’s first ultra-early MG 0000 variety suited to grow in colder areas in the north of France, while PRO Dinara and PRO Katla (MG 000, Poland) are marking Protealis’ commercial entry into Poland, one of Europe’s fastest-growing soybean markets reaching close to 100,000 hectares today. According to the Polish Soybean Association[3], this area has doubled in the last two years, and has potential to reach up to 700,000 hectares. Furthermore, PRO Erebus is Protealis’ second MG 00 soybean variety registered in Germany, combining high yield with excellent early canopy coverage - a crucial trait that supports natural weed suppression. Lastly, PRO Bingo (MG 000, Belgium) strengthens its portfolio with excellent canopy closure and strong yield–protein balance. All five varieties consistently outperformed competitors in independent multi-location registration trials.
“This is a pivotal moment for the company as we now see efforts of technology investment maturing in products and unique USPs that will enable profitable, local soybean cultivation right here in Europe,” said Benjamin Laga, CEO of Protealis. “For years, soybean acreage growth in Europe was constrained by the lack of high-performance varieties adapted to colder climates and by the absence of inoculant solutions truly suited to European soils. Protealis now addressed both of these challenges by combining climate-adapted genetics and advanced breeding technologies - including AI-driven selection - with our proprietary MagNfix™ inoculant into a ready-to-sow solution. This integrated approach enables farmers to cultivate locally adapted soybean varieties that contribute to crop rotation, soil health, and farm profitability.”
Following regulatory approval, Protealis will initiate a phased pre-commercial rollout during the current season with selected distribution partners in key markets including Poland, France and Germany, ahead of a broader commercial launch in 2027.
Topics
Species
